Esperion Therapeutics, Inc.

NasdaqGM:ESPR Stock Report

Market Cap: US$448.9m

Esperion Therapeutics Balance Sheet Health

Financial Health criteria checks 1/6

Esperion Therapeutics has a total shareholder equity of $-455.0M and total debt of $536.4M, which brings its debt-to-equity ratio to -117.9%. Its total assets and total liabilities are $205.8M and $660.8M respectively.

Key information

-117.9%

Debt to equity ratio

US$536.37m

Debt

Interest coverage ration/a
CashUS$82.25m
Equity-US$454.99m
Total liabilitiesUS$660.79m
Total assetsUS$205.80m

Recent financial health updates

No updates

Recent updates

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Feb 28

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Jan 22

Esperion Is Sitting On A Potential Blockbuster Drug

Jan 14

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Jun 19
Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Mar 09
Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Feb 23
Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Aug 26

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Aug 09

Esperion Therapeutics Q2 2022 Earnings Preview

Aug 01

Esperion Therapeutics: 2021 Labors Paying Off In 2022

May 07

Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout

Feb 24

Esperion Therapeutics: A Potential 'Bio Boom' Or Bust In 2022

Jan 20

Esperion: Bullish On Cost-Cutting Ahead Of Expected Demand Inflection

Oct 27

Esperion: Hunting Big Game In The Danger Zone

Aug 05

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year

May 09
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year

Esperion Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 04

Financial Position Analysis

Short Term Liabilities: ESPR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ESPR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ESPR has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ESPR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ESPR has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: Insufficient data to determine if ESPR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.